je.st
news
Tag: asco
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
2014-06-07 20:47:50| Biotech - Topix.net
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.
ASCO: Put Your Future in Focus
2014-06-04 18:59:45| Logistics - Topix.net
A recent video produced by the Association of Schools and Colleges of Optometry takes the question of "why" becoming a doctor of optometry is worthwhile and answers it threefold: the career holder's ability to change lives, the field's many outlets for occupational growth and the continual advancement of technologies and clinical innovations that ... (more)
Down 7%: Clovis' ASCO News
2014-06-03 05:13:14| Logistics - Topix.net
In this video, from Monday's Market Checkup , the Motley Fool's health care-focused investing show, analysts Michael Douglass and David Williamson discuss the side effects and what this could mean for Clovis moving forward.
IntegraGen Presents Data at ASCO 2014 Annual Meeting on microRNA...
2014-06-02 16:39:35| Logistics - Topix.net
IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced that it presented data during the American Society of Clinical Oncology's 2014 Annual Meeting which demonstrates that the oncology biomarker miR-31-3p is predictive of cetuximab effects in wild-type KRAS metastatic ... (more)
Tags: data
meeting
annual
presents
Data on Mercks Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Pembrolizumab as Monotherapy Shows Estimated Overall Survival Rate of 69 Percent at One Year Across 411 Advanced Melanoma Patients with Varying Stages of Disease and Prior Therapy Durable Responses and Consistent Tolerability Profile Observed Across Doses, Including Patients With or Without Prior Ipilimumab Therapy Phase 3 Trials Ongoing or Planned Across Lines of Therapy, Including Adjuvant Treatment CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the companys large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single agent (monotherapy) in 411 patients with advanced melanoma. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: date
data
advanced
study
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »